Table 2.
Comparison of demographics and WMHs between the improved and non-improved groups
| Improved group (n = 15) |
Non-improved group (n = 18) |
P-value | |
|---|---|---|---|
| Age (year, mean ± SD) | 29.5 ± 9.8 | 34.7 ± 11.0 | 0.166 |
| Gender | 1.000 | ||
| Female, n (%) | 13 (86.7%) | 16 (88.9%) | |
| Male, n (%) | 2 (13.3%) | 2 (11.1%) | |
| BMI (kg/m2, mean ± SD) | 19.9 ± 2.3 | 21.1 ± 2.9 | 0.203 |
| Headache characteristics | |||
| Aura, n (%) | 9 (60.0%) | 2 (11.1%) | 0.008* |
| Disease duration (month, quartile) | 72 (24, 144) | 150 (48, 279) | 0.096 |
| Attack frequency (day/month, quartile) | 4.0 (2.0, 7.0) | 2.0 (2.0, 5.5) | 0.555 |
| Attack duration (hour, quartile) | 4.5 (2.0, 10.0) | 11.0 (3.4, 24.0) | 0.204 |
| Visual analogue scale, mean ± SD | 7.0 (6.0, 7.9) | 8.0 (7.0, 9.3) | 0.051 |
| Medications | |||
| Prophylactic medications#, n (%) | 5 (33.3%) | 4 (22.2%) | 0.697 |
| Medication overuse#, n (%) | 1 (6.7%) | 2 (11.1%) | 1.000 |
*A significance level, P < 0.05; #The number of patients who took regular prophylactic medications for more than 3 months or had medication overuse during the follow-up period; SD standard deviation, BMI body mass index